Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 237

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 237
---
 not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published
or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.

Any invitation or inducement
to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities
has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom
in circumstances in which section 21(1) of FSMA does not apply to the company.

In the United Kingdom,
this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to
investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005, or FPO, (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net
worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together
“relevant persons”). The investments to which this document relates are available only to, and any invitation, offer or
agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely
on this document or any of its contents.

Pursuant to section 3A.3 of
National Instrument 33-105 Underwriting Conflicts, or NI 33-105, the underwriters are not required to comply with the disclosure requirements
of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

<div align='center'>143</div>

Stabilization

In connection with this offering,
the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids, and
purchases to cover positions created by short sales. Stabilizing transactions permit bids to purchase shares so long as the stabilizing
bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of
the Ordinary Shares while the offering is in progress.

Over-allotment transactions
involve sales by the underwriters of shares in